RxDoctor Payments Data

Arthur Williams

Infectious Disease · Harrisburg, PANPI 1104924539

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $66,460 of the $95,611 with a category attached, or 69.5%. Gilead accounts for 97.8% of it on its own, with 14 other manufacturers making up the rest. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,611in general payments, 2019–2025

Across 226 payments — averaging $423.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$94K
  • Viiv Healthcare Company$701
  • Novo Nordisk$294
  • Lilly USA, LLC$248
  • Johnson & Johnson$220
  • AbbVie$177
  • plus $461 from 9 others

What the payments were for

  • Consulting fees$5,4506%
  • Speaking & faculty fees$66,46070%
  • Travel & lodging$19,54420%
  • Food & beverage$4,0334%
  • Education$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,611 in reported general payments places this provider in the 95th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala20$87,209
EliquisApixaban37$32,371
JanuviaSitagliptin Phosphate34$26,711
JardianceEmpagliflozin31$24,471
TrulicityDulaglutide12$14,898
XareltoRivaroxaban15$12,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,794
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$4,061
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,969
Albuterol Sulfate HfaAlbuterol Sulfate112$2,866
Atorvastatin Calcium217$2,112
Lisinopril138$975
Omeprazole104$874
Nifedipine ErNifedipine49$837
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic12$835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$93,510$87,20920 claims
PfizerEliquis$15$32,37137 claims
MerckJanuvia$17$26,71134 claims
Lilly USA, LLCTrulicity$248$14,89812 claims
Johnson & JohnsonXarelto$220$12,65715 claims
GSKTrelegy Ellipta$74$6,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →